Siren Care has secured a $9.5 million funding round, led by an $8 million strategic investment from Mölnlycke Health Care, to advance its innovative diabetic foot ulcer (DFU) prevention solutions. This partnership integrates Siren’s temperature-sensing textile technology with Mölnlycke’s expertise in wound care, aiming to reduce DFUs and amputations.

From the press release:

Siren is proud to announce thecompletion of a $9.5m funding round, led by an $8 million strategic investmentby Mölnlycke Health Care, with participation from new and existing investors, tofurther the development and adoption of Siren’s innovative diabetic foot ulcer(DFU) prevention solutions. This marks a pivotal step in transforming DFU careby integrating Siren’s cutting-edge temperature-sensing textile technology withMölnlycke’s expertise in wound care.

More than 830 million people globally live with diabetes1, many of whom are at risk of developing DFUs, leading to severe complications, including amputations. Siren’s flagship product, Siren Socks, uses patented technology to detect early signs of potential foot injuries, reducing the risk of DFUs by up to 68%2 and amputations by 83%2. Coupled with remote patient monitoring services, Siren’s ecosystem provides comprehensive care that enhances patient outcomes, and reduces healthcare costs. 

“This partnership represents a major milestone in our journey to redefine DFU prevention and management,” said Ran Ma, co-founder and CEO ofSiren. “Mölnlycke’s investment underscores the importance of preventive technologies in tackling chronic conditions like DFUs. Together, we aim to empower patients with tools that help them stay healthy and independent while easing the load on healthcare providers. Prevention is the key to avoiding painful, costly, and life-altering complications.”